Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Mevo Health vs OlleveCare

Mevo Health
Graded #326

Higher grade

vs+14
OlleveCare
Graded #497

Lower grade

The verdict

Mevo Health takes it — 60.2/100 to 46.2/100.

Mevo Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mevo Health (Mevo Health LLC, Delaware) is a direct-pay telehealth platform offering compounded semaglutide and tirzepatide in both injection and oral-tablet forms — a rare both-routes, both-molecules menu.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMevo Health +11
56
45
Dose & formulationMevo Health +43
83
40
Clinical oversightMevo Health +14
67
53
Labs & monitoringMevo Health +3
52
49
FulfillmentMevo Health +19
57
38
Contract termsOlleveCare +35
20
55
Mevo Health · left barOlleveCare · right bar

The numbers

MetricMevo HealthOlleveCare
WeighScore60.2/10046.2/100
GradeCC
Scorecard rank#326#497
Semaglutide$199/mo (all doses, compounded)Not disclosed
Tirzepatide$259/mo (all doses, compounded)Not disclosed
CoverageCoverage not published13 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
Mevo Health

Graded #326 · C

Strengths

  • LegitScript verification badge on multiple pages
  • Publishes the FDA compounded-medication disclaimer
  • Four named board-certified physicians disclosed (Wasef, Suppa, Sakla, Chikando)
  • Both semaglutide and tirzepatide in injection and oral-tablet forms — rare in DTC
  • Public entry-level pricing surfaced

Where it loses points

  • States served not listed on any public page
  • Pharmacy partners not named (only '503A U.S. compounding pharmacies' with unlabeled logos)
  • No formal Medical Director role disclosed
  • Only 'as low as' entry pricing shown — no per-dose itemization
  • No SOC 2 certification claimed
OlleveCare

Graded #497 · C

Strengths

  • 13 states listed explicitly (VA, FL, AZ, MA, HI, IA, MD, NM, WA, KS, NY, DC, ID)
  • Both semaglutide and tirzepatide offered — switch molecules without switching platforms
  • Multi-service platform — GLP-1, virtual urgent care, and non-controlled refills with one provider
  • Cash-pay with a superbill option for out-of-network reimbursement
  • Founder Ahmed Emam is named in the footer

Where it loses points

  • Legal entity name not disclosed anywhere — can't be verified in a state registry
  • Pricing not shown before booking — you must enter the intake flow to see the fee
  • Pharmacy partner not named; model appears to fill at your preferred retail pharmacy
  • No medical director or prescribing clinician named — only 'board-certified providers'
  • No LegitScript badge, BBB profile, or HIPAA/SOC 2 seals displayed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard